TITLE:
A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

CONDITION:
Crohn's Disease

INTERVENTION:
Adalimumab (D2E7)

SUMMARY:

      Purpose of the study is to test whether adalimumab can induce clinical remission in subjects
      with active Crohn's disease when compared to placebo (an inactive substance)
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 75 Years
Criteria:

        Inclusion:

          -  Diagnosis of Crohn's disease

          -  CDAI score at baseline of between 220 and 450

          -  Normal laboratory parameters

          -  Willing and able to give informed consent

        Exclusion:

          -  Diagnosis of ulcerative colitis

          -  Women cannot be pregnant or breastfeeding

          -  No previous use of infliximab or other anti-TNF antagonists

          -  No previous history of tuberculosis or listeria infection

          -  No previous history of cancer other than successfully treated skin cancer
      
